Use of a decision aid to resolve uncertainty about radioactive iodine treatment in patients with intermediate-risk thyroid cancer: the Radiance trial
使用决策辅助解决中危甲状腺癌患者放射性碘治疗的不确定性:Radiance 试验
基本信息
- 批准号:10697332
- 负责人:
- 金额:$ 31.22万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-05 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:American Cancer SocietyAreaBenefits and RisksBiological MarkersCancer PatientCancer SurvivorClient satisfactionClinical Practice GuidelineCommunicationConflict (Psychology)DataDecision AidDecision MakingDental cariesDevelopmentDiagnosisDimensionsDistrict of ColumbiaDoseEducationEnrollmentEquilibriumEvaluationFaceFatigueFeedbackFrequenciesFrustrationGuidelinesHospitalsIndividualIntervention TrialKnowledgeMalignant neoplasm of thyroidMeasuresMediatingMediatorMedicalModelingNewly DiagnosedNoseOnline SystemsOperative Surgical ProceduresOral cavityOutcomeParticipantPathway interactionsPatientsPersonsPhasePhysiciansProspective StudiesProtocols documentationPublishingQuality of lifeRadioactive IodineRandomizedRandomized, Controlled TrialsRecommendationRecurrenceRecurrent Malignant NeoplasmRegretsReportingRiskSalivarySalivary GlandsSecond Primary CancersSelf EfficacySiteSurvival RateSymptomsTestingUncertaintyUnited StatesXerostomiaarmcancer biomarkerscancer recurrencechild bearingclinical research sitedisorder riskexperiencehigh risklacrimalpilot testprimary outcomeprototyperadioiodine therapyrecruitreproductivesatisfactionsecondary outcomeside effecttreatment as usualusabilityusual care armweb based decision aidweb site
项目摘要
ABSTRACT. Individuals diagnosed with intermediate risk differentiated thyroid cancer (DTC) encounter
significant uncertainty regarding the risks and benefits of radioactive iodine (RAI). RAI is routine treatment for
patients with high risk DTC based on the documented increased rate of survival. In contrast, RAI is generally
not used for patients with low risk DTC, as it does not decrease recurrence nor increase survival. Due to
absence of data from randomized controlled trials, controversy remains regarding the balance of benefits and
risks for RAI treatment for patients with intermediate risk DTC. Clinical practice guidelines now suggest
consideration of RAI in patients with intermediate risk disease. Thus, most patients with intermediate risk DTC
choose between surgery alone vs surgery plus RAI. Data from our team and others indicate patients report a
lack of information about the potential side effects of RAI including salivary gland damage, nasal and lacrimal
symptoms, reproductive impact, secondary malignancies, and effects on quality of life. Salivary gland damage
occurs among 21-77% of patients after RAI in a dose-dependent manner. Other RAI-dose dependent effects
include lacrimal and nasal symptoms. Patients also report increased fatigue and decreased quality of life,
particularly with complications from RAI. Patients with intermediate risk DTC have a need to balance what is
known about the risks and benefits of RAI. Using established data concerning RAI benefits and compelling
new data about the frequency of side effects due to RAI, we seek to develop and evaluate a decision aid (DA)
to promote informed decisions about RAI treatment among these patients. Guided by the Ottawa Decision
Support Framework, we will first develop and pilot test the DA (UG3 Aim 1). We will use preliminary data, team
input and published guidelines to create an outline of the DA. We will develop a web-based prototype and
conduct usability testing with 16 patients (8 with, 8 without RAI). We will revise the DA and recruit 30 patients
with newly diagnosed intermediate risk DTC for a pilot randomized controlled trial of the DA to examine the
feasibility, usability and satisfaction with the DA. We will compare the DA (n=20) to a usual care (UC)
educational control website (n=10) to explore the effect of the DA on informed choice about RAI, knowledge,
self-efficacy, and decisional conflict and regret at 4 weeks post-randomization. We will make iterative
refinements to the DA. In the UH3 phase (years 3-7; UH3 Aims 2, 3), we will conduct a multi-site randomized
controlled trial of the finalized DA at three clinical sites. We will screen 800 patients with newly diagnosed
intermediate risk DTC and enroll and randomize 400 patients (n=200 DA arm; n=200 UC arm). We will conduct
assessments at baseline and 1 week, 4 weeks and 6 months post-randomization. Our primary outcome is
informed choice at 4 weeks (Aim 2). Secondary outcomes include knowledge, decisional conflict and regret,
and treatment satisfaction. We will explore QOL among all patients at 6 months. We will examine whether self-
efficacy and satisfaction with patient-physician communication mediate the effect of the DA (Aim 3).
摘要。诊断为中等风险分化型甲状腺癌(DTC)的个体
关于放射性碘(RAI)的风险和益处的重大不确定性。RAI是常规治疗,
根据记录的生存率增加,高风险DTC患者。相比之下,RAI通常
不用于低风险DTC患者,因为它不会降低复发率,也不会增加生存率。由于
由于缺乏随机对照试验的数据,关于获益和
中等风险DTC患者的RAI治疗风险。临床实践指南现在建议
考虑中等风险疾病患者的RAI。因此,大多数中等风险DTC患者
选择单独手术还是手术加RAI。来自我们团队和其他人的数据表明,
缺乏关于RAI潜在副作用的信息,包括唾液腺损伤、鼻和泪腺损伤
症状、生殖影响、继发性恶性肿瘤和对生活质量的影响。唾液腺损伤
在RAI后21-77%的患者中以剂量依赖性方式发生。其他RAI剂量依赖性效应
包括泪和鼻症状。患者还报告疲劳增加和生活质量下降,
尤其是RAI的并发症中等风险DTC患者需要平衡
了解RAI的风险和益处。使用有关RAI效益的既定数据,
关于RAI副作用频率的新数据,我们寻求开发和评估决策辅助(DA)
促进这些患者对RAI治疗做出明智的决定。在渥太华决定的指导下
支持框架,我们将首先开发和试点测试DA(UG 3目标1)。我们将使用初步数据,
输入和发布的指导方针,以创建DA的大纲。我们将开发一个基于Web的原型,
对16例患者(8例有RAI,8例无RAI)进行可用性测试。我们将修改DA并招募30名患者
与新诊断的中等风险DTC的试点随机对照试验的DA,以检查
DA的可行性、可用性和满意度。我们将DA(n=20)与常规护理(UC)进行比较
教育控制网站(n=10),以探讨DA对RAI,知识,
随机分组后4周,自我效能、决策冲突和后悔。我们将使迭代
在UH 3阶段(3-7年; UH 3目标2,3),我们将进行多中心随机
在三个临床试验点对最终DA进行对照试验。我们将筛查800名新诊断的
中等风险DTC并招募和随机化400名患者(n=200 DA组; n=200 UC组)。我们会进行
在基线和随机化后1周、4周和6个月进行评估。我们的主要成果是
4周时的知情选择(目标2)。次要结果包括知识,决策冲突和遗憾,
治疗满意度。我们将在6个月时探索所有患者的QOL。我们将研究是否自我-
患者-医生沟通的有效性和满意度介导了DA的效果(目的3)。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KRISTI D. GRAVES其他文献
KRISTI D. GRAVES的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KRISTI D. GRAVES', 18)}}的其他基金
Use of a decision aid to resolve uncertainty about radioactive iodine treatment in patients with intermediate-risk thyroid cancer: the Radiance trial
使用决策辅助解决中危甲状腺癌患者放射性碘治疗的不确定性:Radiance 试验
- 批准号:
10523258 - 财政年份:2022
- 资助金额:
$ 31.22万 - 项目类别:
Programa de ARBOLES Familiares: Assessing Risk of Breast Cancer through Outreach to Latinas with Education and Support
Programa de ARBOLES Familiares:通过向拉丁裔提供教育和支持来评估乳腺癌风险
- 批准号:
10318077 - 财政年份:2017
- 资助金额:
$ 31.22万 - 项目类别:
Programa de ARBOLES Familiares: Assessing Risk of Breast Cancer through Outreach to Latinas with Education and Support
Programa de ARBOLES Familiares:通过向拉丁裔提供教育和支持来评估乳腺癌风险
- 批准号:
9988217 - 财政年份:2017
- 资助金额:
$ 31.22万 - 项目类别:
Programa de ARBOLES Familiares: Assessing Risk of Breast Cancer through Outreach to Latinas with Education and Support
Programa de ARBOLES Familiares:通过向拉丁裔提供教育和支持来评估乳腺癌风险
- 批准号:
9358026 - 财政年份:2017
- 资助金额:
$ 31.22万 - 项目类别:
Programa de ARBOLES Familiares: Assessing Risk of Breast Cancer through Outreach to Latinas with Education and Support
Programa de ARBOLES Familiares:通过向拉丁裔提供教育和支持来评估乳腺癌风险
- 批准号:
9750014 - 财政年份:2017
- 资助金额:
$ 31.22万 - 项目类别:
Capturing the Impact of Craniofacial Damage after Radioiodine Therapy
了解放射性碘治疗后颅面损伤的影响
- 批准号:
9900576 - 财政年份:2016
- 资助金额:
$ 31.22万 - 项目类别:
Capturing the Impact of Craniofacial Damage after Radioiodine Therapy
了解放射性碘治疗后颅面损伤的影响
- 批准号:
9077663 - 财政年份:2016
- 资助金额:
$ 31.22万 - 项目类别:
The Role of Behavioral Science in Personalized Genetic Medicine
行为科学在个性化基因医学中的作用
- 批准号:
7921744 - 财政年份:2009
- 资助金额:
$ 31.22万 - 项目类别:
The Role of Behavioral Science in Personalized Genetic Medicine
行为科学在个性化基因医学中的作用
- 批准号:
8214614 - 财政年份:2008
- 资助金额:
$ 31.22万 - 项目类别:
The Role of Behavioral Science in Personalized Genetic Medicine
行为科学在个性化基因医学中的作用
- 批准号:
7359839 - 财政年份:2008
- 资助金额:
$ 31.22万 - 项目类别:
相似国自然基金
层出镰刀菌氮代谢调控因子AreA 介导伏马菌素 FB1 生物合成的作用机理
- 批准号:2021JJ40433
- 批准年份:2021
- 资助金额:0.0 万元
- 项目类别:省市级项目
寄主诱导梢腐病菌AreA和CYP51基因沉默增强甘蔗抗病性机制解析
- 批准号:32001603
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
AREA国际经济模型的移植.改进和应用
- 批准号:18870435
- 批准年份:1988
- 资助金额:2.0 万元
- 项目类别:面上项目
相似海外基金
Onboarding Rural Area Mathematics and Physical Science Scholars
农村地区数学和物理科学学者的入职
- 批准号:
2322614 - 财政年份:2024
- 资助金额:
$ 31.22万 - 项目类别:
Standard Grant
TRACK-UK: Synthesized Census and Small Area Statistics for Transport and Energy
TRACK-UK:交通和能源综合人口普查和小区域统计
- 批准号:
ES/Z50290X/1 - 财政年份:2024
- 资助金额:
$ 31.22万 - 项目类别:
Research Grant
Wide-area low-cost sustainable ocean temperature and velocity structure extraction using distributed fibre optic sensing within legacy seafloor cables
使用传统海底电缆中的分布式光纤传感进行广域低成本可持续海洋温度和速度结构提取
- 批准号:
NE/Y003365/1 - 财政年份:2024
- 资助金额:
$ 31.22万 - 项目类别:
Research Grant
Point-scanning confocal with area detector
点扫描共焦与区域检测器
- 批准号:
534092360 - 财政年份:2024
- 资助金额:
$ 31.22万 - 项目类别:
Major Research Instrumentation
Collaborative Research: Scalable Manufacturing of Large-Area Thin Films of Metal-Organic Frameworks for Separations Applications
合作研究:用于分离应用的大面积金属有机框架薄膜的可扩展制造
- 批准号:
2326714 - 财政年份:2024
- 资助金额:
$ 31.22万 - 项目类别:
Standard Grant
Collaborative Research: Scalable Manufacturing of Large-Area Thin Films of Metal-Organic Frameworks for Separations Applications
合作研究:用于分离应用的大面积金属有机框架薄膜的可扩展制造
- 批准号:
2326713 - 财政年份:2024
- 资助金额:
$ 31.22万 - 项目类别:
Standard Grant
Unlicensed Low-Power Wide Area Networks for Location-based Services
用于基于位置的服务的免许可低功耗广域网
- 批准号:
24K20765 - 财政年份:2024
- 资助金额:
$ 31.22万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
RAPID: Collaborative Research: Multifaceted Data Collection on the Aftermath of the March 26, 2024 Francis Scott Key Bridge Collapse in the DC-Maryland-Virginia Area
RAPID:协作研究:2024 年 3 月 26 日 DC-马里兰-弗吉尼亚地区 Francis Scott Key 大桥倒塌事故后果的多方面数据收集
- 批准号:
2427233 - 财政年份:2024
- 资助金额:
$ 31.22万 - 项目类别:
Standard Grant
RAPID: Collaborative Research: Multifaceted Data Collection on the Aftermath of the March 26, 2024 Francis Scott Key Bridge Collapse in the DC-Maryland-Virginia Area
RAPID:协作研究:2024 年 3 月 26 日 DC-马里兰-弗吉尼亚地区 Francis Scott Key 大桥倒塌事故后果的多方面数据收集
- 批准号:
2427232 - 财政年份:2024
- 资助金额:
$ 31.22万 - 项目类别:
Standard Grant
RAPID: Collaborative Research: Multifaceted Data Collection on the Aftermath of the March 26, 2024 Francis Scott Key Bridge Collapse in the DC-Maryland-Virginia Area
RAPID:协作研究:2024 年 3 月 26 日 DC-马里兰-弗吉尼亚地区 Francis Scott Key 大桥倒塌事故后果的多方面数据收集
- 批准号:
2427231 - 财政年份:2024
- 资助金额:
$ 31.22万 - 项目类别:
Standard Grant